

Please join us for a promotional program
intended to educate healthcare practitioners

Could it be more than occasional constipation?

*Time to have a deeper conversation
with your patient*

**INCLUDING A CLINICAL REVIEW OF
LINZESS® (linaclotide) capsules**

GUEST SPEAKER:

Kimberly Orleck, MPH, RD, PA-C
Atlanta Gastroenterology Associates

**Thursday, January 12, 2023
at 6:30 PM**

Georgia Blue

202 Baptist Drive
Madison, Mississippi 39110

Please RSVP for this program by using the following link:

abbvie.meintl.com/JOB04-LZ01-23

For questions, contact your AbbVie Representative
Richard Nelson (662) 316-0057

INDICATIONS AND USAGE

LINZESS® (linaclotide) is indicated in adults for the treatment of both irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC).

IMPORTANT SAFETY INFORMATION

WARNING: RISK OF SERIOUS DEHYDRATION IN PEDIATRIC PATIENTS LESS THAN 2 YEARS OF AGE

LINZESS is contraindicated in patients less than 2 years of age; in nonclinical studies in neonatal mice, administration of a single, clinically relevant adult oral dose of linaclotide caused deaths due to dehydration.

Please see additional Important Safety Information on pages 1 and 2, including Boxed Warning.

Please see full [Prescribing Information](https://www.rxabbvie.com/pdf/linzess_pi.pdf), including Boxed Warning, or visit https://www.rxabbvie.com/pdf/linzess_pi.pdf.

In accordance with the PhRMA Code on Interactions with Healthcare Professionals, attendance at this program is limited to healthcare professionals who practice in relevant specialties.

AbbVie tracks and reports payments and transfers of value to healthcare professionals under applicable state and federal reporting obligations.

Alcohol will no longer be provided by AbbVie at programs.

Linzess[®]
(linaclotide) capsules
72 mcg • 145 mcg • 290 mcg